Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
of disease recurrence, the association of distant metastasis and biomarker profile in early-stage breastcancer has not been adequately studied in prospective studies of staging investigation. The benefit and risks of the routine use of biomarker profiles to assess for distant metastasis is still unclear and, thus, its use to guide decisions on imaging staging for clinical early-stage breastcancer is not recommended regardless of whether the patient is going for neoadjuvant therapy. Guideline 1-14 (...) , and PET/CT may add unnecessary anxiety and resource use. Therefore, the use of PET/CT, as part of the baseline staging in women clinically diagnosed with early-stage breastcancer (I, II) and with no symptoms for distant metastasis is not recommended at this time. ? Although women with triple negative and human epidermal growth factor receptor 2- positive (HER2+) breastcancer have an increased risk of disease recurrence, the association of distant metastasis and biomarker profile in early-stage
breastcancer were included. Randomization was in a 1:1 ratio and was stratified according to the presence of liver or lung metastases (yes/no), prior chemotherapy for advanced disease (yes/no) and endocrine combination partner (tamoxifen + goserelin or NSAI + goserelin). All patients in the study were pre- or perimenopausal. Their tumours had to be not amenable to resection or radiotherapy with curative intent. In addition, the patients had to have an Eastern Cooperative Oncology Group Performance (...) Ribociclib, BreastNeoplasms, Benefit Assessment, NCT02422615, NCT02278120 Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-06 Ribociclib (breastcancer
preoperative radiography and radionuclide bone scanning performed on stage I asymptomatic breastcancer patients . Only 1 of 633 patients with stage I disease had metastatic bone disease detected. Several other nonrandomized clinical studies have also documented the low yield and lack of utility of radionuclide bone scanning for patients with stage I breastcarcinoma [6-9]. Despite the low yield of bone scans, many clinicians order baseline bone scans for comparison with subsequent scans performed when (...) to be <0.5% in asymptomatic women who had routine chest radiographs after the diagnosis of stage I breastcarcinoma [5,19,20]. In a study of 412 women with newly diagnosed breastcancer, chest radiographs only showed metastases in women previously classified as having stage III disease . Furthermore, false-positive chest radiographs can lead to expensive diagnostic workups. Two large Italian randomized control studies failed to show a significant outcome benefit when routine chest radiography
Type and timing of menopausal hormone therapy and breastcancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Published findings on breastcancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence.Principal analyses used (...) never users.During prospective follow-up, 108 647 postmenopausal women developed breastcancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breastcancer risks, which increased steadily with duration of use
Prophylactic antibiotics to prevent surgical site infection after breastcancer surgery. Surgery has been used as part of breastcancer treatment for centuries; however any surgical procedure has the potential risk of infection. Infection rates for surgical treatment of breastcancer are documented at between 3% and 15%, higher than average for a clean surgical procedure. Pre- and perioperative antibiotics have been found to be useful in lowering infection rates in other surgical groups, yet (...) there is no consensus on the use of prophylactic antibiotics for breastcancer surgery. This is an update of a Cochrane Review first published in 2005 and last updated in 2014.To determine the effects of prophylactic (pre- or perioperative) antibiotics on the incidence of surgical site infection (SSI) after breastcancer surgery.For this fourth update, in August 2018 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process
trials were combined by using a profile likelihood random-effects model.Probability of breastcancer in individuals (area under the receiver operating characteristic curve [AUC]); incidence of breastcancer, fractures, thromboembolic events, coronary heart disease events, stroke, endometrial cancer, and cataracts; and mortality.A total of 46 studies (82 articles [>5 million participants]) were included. Eighteen risk assessment methods in 25 studies reported low accuracy in predicting the probability (...) Medication Use for the Risk Reduction of Primary BreastCancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Medications to reduce risk of breastcancer are effective for women at increased risk but also cause adverse effects.To update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breastcancer in women.Cochrane Central Register of Controlled Trials
in women without preexisting breastcancer or ductal carcinoma in situ.The USPSTF found convincing evidence that risk assessment tools can predict the number of cases of breastcancer expected to develop in a population. However, these risk assessment tools perform modestly at best in discriminating between individual women who will or will not develop breastcancer. The USPSTF found convincing evidence that risk-reducing medications (tamoxifen, raloxifene, or aromatase inhibitors) provide at least (...) a moderate benefit in reducing risk for invasive estrogen receptor-positive breastcancer in postmenopausal women at increased risk for breastcancer. The USPSTF found that the benefits of taking tamoxifen, raloxifene, and aromatase inhibitors to reduce risk for breastcancer are no greater than small in women not at increased risk for the disease. The USPSTF found convincing evidence that tamoxifen and raloxifene and adequate evidence that aromatase inhibitors are associated with small to moderate harms
versus non-taxane-containing regimens in women with operable breastcancer were included. Studies of women receiving neoadjuvant chemotherapy were excluded.Two review authors independently extracted data and assessed risk of bias and quality of the evidence using the GRADE approach. Hazard ratios (HRs) were derived for time-to-event outcomes, and meta-analysis was performed using a fixed-effect model. The primary outcome measure was overall survival (OS); disease-free survival (DFS) was a secondary (...) of studies supports the use of taxane-containing adjuvant chemotherapy regimens, with improvement in overall survival and disease-free survival for women with operable early breastcancer. This benefit persisted when analyses strictly compared a taxane-containing regimen versus the same regimen without a taxane or the same regimen with another drug that was substituted for the taxane. Preliminary evidence suggests that taxanes are more effective for women with lymph node-positive disease than for those
Internal mammary node irradiation for people with high-risk early breastcancer Internal mammary node irradiation - Health Technology Wales > Internal mammary node irradiation Internal mammary node irradiation Topic Status Complete Internal mammary node irradiation for people with high-risk early breastcancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence (...) on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER031 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact
Partial breast irradiation for people with early breastcancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breastcancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used
cancer. The USPSTF found that the benefits of taking tamoxifen, raloxifene, and aromatase inhibitors to reduce risk for breastcancer are no greater than small in women not at increased risk for the disease. Potential Harms of Risk-Reducing Medications The USPSTF found convincing evidence that tamoxifen and raloxifene are associated with small to moderate harms. Tamoxifen and raloxifene increase risk for venous thromboembolic events (VTEs); tamoxifen increases risk more than raloxifene (...) to reduce risk of breastcancer outweigh the potential benefits in women not at increased risk for the disease. Clinicians should discuss the limitations of current clinical risk assessment tools for predicting an individual’s future risk of breastcancer when discussing the benefits and harms of risk-reducing medications with women. Clinical Considerations Patient Population Under Consideration This recommendation applies to asymptomatic women 35 years and older, including women with previous benign
Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breastcancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breastcancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services
Resection of Cavity Shave Margins in Stage 0-III BreastCancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial Single-center studies have demonstrated that resection of cavity shave margins (CSM) halves the rate of positive margins and re-excision in breastcancer patients undergoing partial mastectomy (PM). We sought to determine if these findings were externally generalizable across practice settings.In this multicenter randomized (...) controlled trial occurring in 9 centers across the United States, stage 0-III breastcancer patients undergoing PM were randomly assigned to either have resection of CSM ("shave" group) or not ("no shave" group). Randomization occurred intraoperatively, after the surgeon had completed their standard PM. Primary outcome measures were positive margin and re-excision rates.Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial. Four patients (2 in each arm) did not meet inclusion
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable BreastCancer Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable BreastCancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00948 Journal of Clinical Oncology - published online before print June 17, 2019 PMID: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable BreastCancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline , MD, PhD 1 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 3 x Vandana G. Abramson ; , MD 2 x Nofisat Ismaila ; , MD 4 x Kimberly H. Allison ; , MD 5 x Carey K. Anders ; , MS, MFA 6 x Diana T. Chingos ; , MD 7 x Andrea
Clinical utility of genomic signatures in early-stage breastcancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breastcancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) aids for the prescribing of adjuvant chemotherapy (ACT) in certain cases of early breastcancer. Conclusions and results The HAS report concludes that GS are not intended to replace standard clinicopathological criteria (SCPC), which are considered to play a crucial role in the prescribing of ACT for early breastcancer. In light of inadequate 2 and/or lack of clinical data respectively found in first and second generation tests, the HAS considers it to be premature to recommend routine use of GS
Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After BreastCancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breastcancer surgery. Although there is insufficient evidence to support any preventative strategy, prior literature suggests the possible efficacy (...) of intravenous lidocaine and perioperative pregabalin in preventing persistent pain after surgery. To determine feasibility of conducting a larger definitive trial, we conducted a multicenter 2 × 2 factorial, randomized, placebo-controlled pilot trial of 100 female patients undergoing breastcancer surgery. Patients were randomized to receive an intraoperative lidocaine infusion (1.5 mg/kg bolus followed by 2 mg/kg/h) or placebo and perioperative pregabalin (300 mg preoperatively, 75 mg twice daily for 9
Strategies to Identify Women at High Risk of Advanced BreastCancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breastcancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breastcancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breastcancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at BreastCancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data
Abemaciclib (Verzenios) for the treatment of metastatic breastcancer Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer | Report | National Health Care Institute You are here: Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer Search within English part of National Health Care Institute Search Abemaciclib (Verzenios®) for the treatment of metastatic breastcancer Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios® (...) ) for the treatment of metastatic breastcancer. Due to its expected high costs the Minister of Health, Welfare and Sport (VWS) has placed tisagenlecleucel in the so-called ‘waiting room’ or ‘sluice’ for expensive drugs. These products can only be accepted into the insured package after the Zorginstituut has advised on their inclusion in the insured package and, where applicable, subject to Ministry negotiations to arrive at a financial arrangement with the supplier. The Zorginstituut was advised by two